Keep up to date with every new upload!

Join free & follow Tumor Immunology Round Table
Share
  • 10 years ago
N-acetyllactosamine (lacNAC) reverts human TIL anergy ex vivo.

N-acetyllactosamine (lacNAC) reverts human TIL anergy ex vivo.

Hello

In this edition of the podcast I will discuss a paper published by
Demotte and collaborators published this year in the journal Immunity
"Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes" vol 28, pag 414 of April 2008.

In this paper the authors show that LacNAC can compete for galectin-3 binding freeing TCR from TIL to colocalize with CD8 and allow the recovery of efector functional on ex vivo freshly isolated TIL from ovarian cancer and gastric cancer.

See you next time.

Comments